Publications by authors named "Kawa K Ajgeiy"
Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the real-world effectiveness of biologics in treating psoriasis by looking at treatment discontinuation and off-label dose escalation, rather than relying solely on traditional drug survival studies.
- Researchers analyzed data from a nationwide registry (DERMBIO) involving patients treated with adalimumab, secukinumab, and ustekinumab from 2007 to 2019, focusing on composite, discontinuation, and escalation outcomes.
- Findings indicated that secukinumab had a lower overall risk of treatment discontinuation compared to ustekinumab, but a higher risk for discontinuation when compared to adalimumab, with bio-naive patients on secukinumab showing a similar discontinuation risk as those
Background: Immunosuppressive agents may increase the risk of infections with human alphaherpesviruses.
Methods: We included all adult patients with moderate to severe psoriasis who initiated methotrexate (MTX) or biologic agents in a retrospective cohort study. An episode of alphaherpesviruses infection was defined as filling a prescription for systemic acyclovir, valacyclovir, or famciclovir.
Importance: Identifying the optimal long-term biologic therapy for patients with psoriasis is often done through trial and error.
Objective: To identify the optimal biologic therapy for individual patients with psoriasis using predictive statistical and machine learning models.
Design, Setting, And Participants: This population-based cohort study used data from Danish nationwide registries, primarily DERMBIO, and included adult patients treated for moderate-to-severe psoriasis with biologics.
Article Synopsis
- Identifying patient characteristics that predict how well they respond to biologic treatments for psoriasis could help avoid costly medication changes.
- The study analyzed data from 2,384 biologic-naïve patients treated with various biologics, assessing factors like smoking and bodyweight on treatment outcomes.
- Results showed that higher bodyweight and smoking decreased the likelihood of achieving a successful treatment response after 6 months, particularly for certain biologics.
Article Synopsis
- Adalimumab biosimilars have shown similar effectiveness to the original adalimumab (Humira), but there's a lack of real-world data on their performance.
- The study aimed to evaluate the outcomes of patients switching from the original adalimumab to its biosimilar in treating psoriasis, using records from a Danish registry.
- Results indicated that both groups had high drug retention rates after one year, with the biosimilar cohort showing a retention rate of 92.0%.
Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.
Acta Derm Venereol
January 2021
Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0-≤2, PASI > 2-≤ 4, and PASI > 4.
View Article and Find Full Text PDFTo asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibitor induced angioedema with regard to demographics, risk factors, family history of angioedema, hospitalization, airway management, outcome, and use of diagnostic codes used for the condition. Cohort study. .
View Article and Find Full Text PDF